Spots Global Cancer Trial Database for encorafenib
Every month we try and update this database with for encorafenib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) | NCT02675946 | Solid Tumors GI Cancer | CGX1321 Pembrolizumab encorafenib cetuximab | 18 Years - | Curegenix Inc. | |
| ENCOrafenib With Binimetinib in bRAF NSCLC | NCT04526782 | Non Small Cell ... BRAF V600E | Encorafenib 75 ... Binimetinib 15 ... | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors | NCT03864042 | Advanced Solid ... Metastatic Mela... | losartan dextromethorpha... caffeine omeprazole midazolam rosuvastatin bupropion immed... encorafenib binimetinib modafinil | 18 Years - | Pfizer | |
| Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma | NCT02902042 | Malignant Melan... | Encorafenib Binimetinib Pembrolizumab Pembrolizumab a... | 18 Years - | University Hospital, Essen | |
| Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma | NCT02910700 | Metastatic Mali... Metastatic Mela... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable Me... | Binimetinib Dabrafenib Encorafenib Laboratory Biom... Nivolumab Pharmacological... Trametinib | 18 Years - | M.D. Anderson Cancer Center | |
| Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma | NCT02902042 | Malignant Melan... | Encorafenib Binimetinib Pembrolizumab Pembrolizumab a... | 18 Years - | University Hospital, Essen | |
| A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | NCT04511013 | Acral Lentigino... Clinical Stage ... Metastatic Cuta... Metastatic Mali... Metastatic Mela... Metastatic Muco... Pathologic Stag... | Binimetinib Encorafenib Ipilimumab Nivolumab | 18 Years - | SWOG Cancer Research Network | |
| PF-07284892 in Participants With Advanced Solid Tumors | NCT04800822 | Solid Tumor | PF-07284892 lorlatinib binimetinib cetuximab encorafenib | 18 Years - | Pfizer | |
| Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer | NCT05710406 | Colon Adenocarc... Microsatellite ... Stage IIB Colon... Stage IIC Colon... Stage III Colon... | Encorafenib Cetuximab Biospecimen Col... Computed Tomogr... Magnetic Resona... Patient Observa... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Melanoma Metastasized to the Brain and Steroids | NCT03563729 | Malignant Melan... | Pembrolizumab I... Ipilimumab Inje... Nivolumab Injec... Encorafenib Binimetinib Dabrafenib Trametinib | 18 Years - | Herlev Hospital | |
| Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma | NCT06194929 | Melanoma | Defactinib Avutometinib Encorafenib | 18 Years - | University of Utah | |
| Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE | NCT04720768 | Melanoma Metastasis | Binimetinib Encorafenib Palbociclib | 18 Years - 100 Years | Peter MacCallum Cancer Centre, Australia | |
| A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors | NCT05538130 | Melanoma Glioma Thyroid Cancer Non-Small Cell ... Malignant Neopl... Brain Neoplasms Colorectal Canc... | PF-07799544 PF-07799933 encorafenib | 16 Years - | Pfizer | |
| Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement | NCT04221438 | Melanoma of Unk... Metastatic Mali... Pathologic Stag... Pathologic Stag... Pathologic Stag... Recurrent Cutan... | Binimetinib Computed Tomogr... Conventional Su... Encorafenib Fluorothymidine... Positron Emissi... | 18 Years - | Eastern Cooperative Oncology Group | |
| A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers | NCT03843775 | Advanced BRAF M... | Binimetinib Encorafenib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer | NCT05217446 | Metastatic Colo... | Encorafenib Cetuximab Pembrolizumab | 16 Years - | Pfizer | |
| Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation | NCT05308446 | Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Recta... Stage IV Colon ... Stage IV Rectal... Unresectable Co... Unresectable Re... | Cetuximab Encorafenib Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma | NCT05304546 | Malignant Melan... Metastatic Mela... Immunotherapy BRAF V600E Malignant Melan... | Pembrolizumab Encorafenib Binimetinib | 18 Years - | Sheba Medical Center | |
| Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement | NCT04221438 | Melanoma of Unk... Metastatic Mali... Pathologic Stag... Pathologic Stag... Pathologic Stag... Recurrent Cutan... | Binimetinib Computed Tomogr... Conventional Su... Encorafenib Fluorothymidine... Positron Emissi... | 18 Years - | Eastern Cooperative Oncology Group | |
| Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer | NCT03693170 | BRAF V600E-muta... | encorafenib Binimetinib Cetuximab | 18 Years - | Pierre Fabre Medicament | |
| A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. | NCT05004350 | BRAF V600E Metastatic Colo... | Encorafenib Cetuximab FOLFIRI | 18 Years - | Pierre Fabre Medicament | |
| Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer | NCT04061980 | BRAF NP_004324.... BRAF V600E Muta... Metastatic Thyr... Refractory Thyr... Stage IV Differ... Stage IVA Diffe... Stage IVB Diffe... | Binimetinib Encorafenib Nivolumab | 18 Years - | Providence Health & Services | |
| A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | NCT02857270 | Advanced Cancer Metastatic Mela... Metastatic Non-... Colorectal Canc... | LY3214996 Midazolam Abemaciclib Nab-paclitaxel Gemcitabine Encorafenib Cetuximab | 18 Years - | Eli Lilly and Company | |
| Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy | NCT05985954 | Metastatic Colo... | Cetuximab Ulixertinib Encorafenib | 18 Years - | M.D. Anderson Cancer Center | |
| Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE | NCT04720768 | Melanoma Metastasis | Binimetinib Encorafenib Palbociclib | 18 Years - 100 Years | Peter MacCallum Cancer Centre, Australia | |
| Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma | NCT03543969 | Melanoma (Skin) Skin Cancer Skin Melanoma Skin Carcinoma | Encorafenib Binimetinib Nivolumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment | NCT04045691 | Melanoma Stage ... Melanoma Stage ... | Encorafenib Binimetinib | 18 Years - | Pierre Fabre Pharma GmbH | |
| Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy | NCT05985954 | Metastatic Colo... | Cetuximab Ulixertinib Encorafenib | 18 Years - | M.D. Anderson Cancer Center | |
| Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation | NCT04390243 | Locally Advance... Metastatic Panc... Recurrent Pancr... Stage III Pancr... Stage IV Pancre... | Binimetinib Encorafenib | 18 Years - | Academic and Community Cancer Research United | |
| Personalized Medicine for Advanced Biliary Cancer Patients | NCT05615818 | Biliary Tract N... | Futibatinib Ivosidenib Zanidatamab Trastuzumab Neratinib Encorafenib Binimetinib Niraparib Cisplatin Gemcitabine | 18 Years - | UNICANCER | |
| A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib | NCT02382549 | Melanoma | BRAF inhibitor 6MHP MEK inhibitor | 18 Years - | University of Virginia | |
| A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies | NCT05957367 | Colorectal Canc... GIST | DCC-3116 Ripretinib Cetuximab Encorafenib | 18 Years - | Deciphera Pharmaceuticals LLC | |
| Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer | NCT04061980 | BRAF NP_004324.... BRAF V600E Muta... Metastatic Thyr... Refractory Thyr... Stage IV Differ... Stage IVA Diffe... Stage IVB Diffe... | Binimetinib Encorafenib Nivolumab | 18 Years - | Providence Health & Services | |
| Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL | NCT04324112 | Hairy Cell Leuk... | binimetinib Encorafenib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer | NCT05725200 | Metastatic Colo... | Alectinib Cetuximab Crizotinib Dasatinib Everolimus Encorafenib Gemcitabine Idelalisib Larotrectinib Methotrexate Palbociclib Panobinostat Pembrolizumab Petrozumab Trastuzumab Talazoparib Venetoclax | 18 Years - | Oslo University Hospital | |
| A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | NCT02857270 | Advanced Cancer Metastatic Mela... Metastatic Non-... Colorectal Canc... | LY3214996 Midazolam Abemaciclib Nab-paclitaxel Gemcitabine Encorafenib Cetuximab | 18 Years - | Eli Lilly and Company | |
| Melanoma Metastasized to the Brain and Steroids | NCT03563729 | Malignant Melan... | Pembrolizumab I... Ipilimumab Inje... Nivolumab Injec... Encorafenib Binimetinib Dabrafenib Trametinib | 18 Years - | Herlev Hospital | |
| Combination Therapy for BRAF-V600E Metastatic CRCm | NCT06411600 | Metastatic Colo... | Encorafenib Cetuximab Bevacizumab | 18 Years - | Vall d'Hebron Institute of Oncology | |
| A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib | NCT02382549 | Melanoma | BRAF inhibitor 6MHP MEK inhibitor | 18 Years - | University of Virginia | |
| Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations | NCT03839342 | Solid Tumor | Binimetinib Encorafenib | 18 Years - | University Health Network, Toronto | |
| Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer | NCT05710406 | Colon Adenocarc... Microsatellite ... Stage IIB Colon... Stage IIC Colon... Stage III Colon... | Encorafenib Cetuximab Biospecimen Col... Computed Tomogr... Magnetic Resona... Patient Observa... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer | NCT04017650 | BRAF NP_004324.... Metastatic Colo... Metastatic Micr... Metastatic Rect... Progressive Dis... Recurrent Color... Stage III Color... Stage IIIA Colo... Stage IIIB Colo... Stage IIIC Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color... Unresectable Co... Unresectable Re... | Cetuximab Encorafenib Nivolumab | 18 Years - | M.D. Anderson Cancer Center | |
| Melanoma Metastasized to the Brain and Steroids | NCT03563729 | Malignant Melan... | Pembrolizumab I... Ipilimumab Inje... Nivolumab Injec... Encorafenib Binimetinib Dabrafenib Trametinib | 18 Years - | Herlev Hospital | |
| Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer | NCT04017650 | BRAF NP_004324.... Metastatic Colo... Metastatic Micr... Metastatic Rect... Progressive Dis... Recurrent Color... Stage III Color... Stage IIIA Colo... Stage IIIB Colo... Stage IIIC Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color... Unresectable Co... Unresectable Re... | Cetuximab Encorafenib Nivolumab | 18 Years - | M.D. Anderson Cancer Center | |
| Study to Evaluate the Efficacy and Safety of Cetuximab in Combination With Encorafenib Plus Binimetinib as Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer | NCT06207656 | Colorectal Canc... | EBC | 18 Years - | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | |
| A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors | NCT05538130 | Melanoma Glioma Thyroid Cancer Non-Small Cell ... Malignant Neopl... Brain Neoplasms Colorectal Canc... | PF-07799544 PF-07799933 encorafenib | 16 Years - | Pfizer | |
| Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer | NCT04044430 | Metastatic Colo... Metastatic Colo... Metastatic Micr... Metastatic Rect... Stage III Colon... Stage III Color... Stage III Recta... Stage IIIA Colo... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Colore... Stage IV Rectal... Stage IVA Colon... Stage IVA Color... Stage IVA Recta... Stage IVB Colon... Stage IVB Color... Stage IVB Recta... Stage IVC Colon... Stage IVC Color... Stage IVC Recta... | Binimetinib Encorafenib Nivolumab Questionnaire A... | 18 Years - | University of California, San Francisco | |
| An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer | NCT03915951 | Non-small Cell ... | encorafenib binimetinib | 18 Years - | Pfizer | |
| Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma | NCT05304546 | Malignant Melan... Metastatic Mela... Immunotherapy BRAF V600E Malignant Melan... | Pembrolizumab Encorafenib Binimetinib | 18 Years - | Sheba Medical Center | |
| Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US | NCT05260684 | Melanoma | Encorafenib Binimetinib Vemurafenib Cobimetinib Dabrafenib Trametinib | 18 Years - | Pfizer | |
| Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment | NCT04045691 | Melanoma Stage ... Melanoma Stage ... | Encorafenib Binimetinib | 18 Years - | Pierre Fabre Pharma GmbH | |
| A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies | NCT05957367 | Colorectal Canc... GIST | DCC-3116 Ripretinib Cetuximab Encorafenib | 18 Years - | Deciphera Pharmaceuticals LLC | |
| Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases | NCT05026983 | Clinical Stage ... Metastatic Mela... Pathologic Stag... | Binimetinib Encorafenib Questionnaire A... | 18 Years - | M.D. Anderson Cancer Center | |
| Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE | NCT04720768 | Melanoma Metastasis | Binimetinib Encorafenib Palbociclib | 18 Years - 100 Years | Peter MacCallum Cancer Centre, Australia | |
| Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors | NCT05003622 | BRAF V600E Unre... BRAF V600E Meta... Melanoma | Encorafenib | 18 Years - | Pierre Fabre Medicament | |
| BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA) | NCT02834364 | Relapsed or Ref... Patients With B... | Encorafenib Binimetinib | 18 Years - | University of Heidelberg Medical Center | |
| ZN-c3 in Adult Participants With Metastatic Colorectal Cancer | NCT05743036 | Metastatic Colo... | ZN-c3 Encorafenib Cetuximab | 18 Years - | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | |
| A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer | NCT04607421 | Neoplasms | Encorafenib Cetuximab Oxaliplatin Irinotecan Leucovorin 5-FU Capecitabine Bevacizumab | 16 Years - | Pfizer | |
| Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer | NCT03693170 | BRAF V600E-muta... | encorafenib Binimetinib Cetuximab | 18 Years - | Pierre Fabre Medicament | |
| CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) | NCT02675946 | Solid Tumors GI Cancer | CGX1321 Pembrolizumab encorafenib cetuximab | 18 Years - | Curegenix Inc. | |
| CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) | NCT02675946 | Solid Tumors GI Cancer | CGX1321 Pembrolizumab encorafenib cetuximab | 18 Years - | Curegenix Inc. | |
| Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer | NCT04017650 | BRAF NP_004324.... Metastatic Colo... Metastatic Micr... Metastatic Rect... Progressive Dis... Recurrent Color... Stage III Color... Stage IIIA Colo... Stage IIIB Colo... Stage IIIC Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color... Unresectable Co... Unresectable Re... | Cetuximab Encorafenib Nivolumab | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study) | NCT04585815 | Carcinoma, Non-... | Sasanlimab Pref... Encorafenib Binimetinib Sasanlimab Axitinib SEA-TGT | 18 Years - | Pfizer | |
| An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer | NCT03915951 | Non-small Cell ... | encorafenib binimetinib | 18 Years - | Pfizer | |
| Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US | NCT05260684 | Melanoma | Encorafenib Binimetinib Vemurafenib Cobimetinib Dabrafenib Trametinib | 18 Years - | Pfizer | |
| Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation | NCT05308446 | Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Recta... Stage IV Colon ... Stage IV Rectal... Unresectable Co... Unresectable Re... | Cetuximab Encorafenib Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| PF-07284892 in Participants With Advanced Solid Tumors | NCT04800822 | Solid Tumor | PF-07284892 lorlatinib binimetinib cetuximab encorafenib | 18 Years - | Pfizer | |
| Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma | NCT06194929 | Melanoma | Defactinib Avutometinib Encorafenib | 18 Years - | University of Utah | |
| A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers | NCT03843775 | Advanced BRAF M... | Binimetinib Encorafenib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. | NCT05004350 | BRAF V600E Metastatic Colo... | Encorafenib Cetuximab FOLFIRI | 18 Years - | Pierre Fabre Medicament | |
| Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations | NCT03839342 | Solid Tumor | Binimetinib Encorafenib | 18 Years - | University Health Network, Toronto | |
| A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer | NCT05217446 | Metastatic Colo... | Encorafenib Cetuximab Pembrolizumab | 16 Years - | Pfizer | |
| Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study | NCT04801966 | Cancer | Trametinib Cobimetinib Binimetinib Alpelisib Vemurafenib Dabrafenib Encorafenib Palbociclib Olaparib Ribociclib Abemaciclib Talazoparib Nivolumab Atezolizumab Pembrolizumab | 2 Years - | Peter MacCallum Cancer Centre, Australia | |
| Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer | NCT05195632 | Non-Small Cell ... | Encorafenib Binimetinib | 18 Years - | Pierre Fabre Medicament | |
| Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma | NCT06194929 | Melanoma | Defactinib Avutometinib Encorafenib | 18 Years - | University of Utah | |
| ZN-c3 in Adult Participants With Metastatic Colorectal Cancer | NCT05743036 | Metastatic Colo... | ZN-c3 Encorafenib Cetuximab | 18 Years - | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | |
| Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer | NCT03693170 | BRAF V600E-muta... | encorafenib Binimetinib Cetuximab | 18 Years - | Pierre Fabre Medicament | |
| A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer | NCT05217446 | Metastatic Colo... | Encorafenib Cetuximab Pembrolizumab | 16 Years - | Pfizer |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
